Skip to main content
CSL Behring Awards Emerging Coagulation Specialists Across the Globe to Support Advancements in the Care of Patients with Bleeding Disorders
CSL Behring today announced that the company has named five recipients of the 2016 CSL Behring Professor Heimburger Award for coagulation research at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla.
  • Five start-up grants totaling $110,000 awarded by CSL Behring
  • The 2016 CSL Behring Professor Heimburger Awards demonstrate the global biotherapeutics leader’s 100-year promise to support pioneering research that improves patient care
  • Recipients recognized by CSL Behring during the World Federation of Hemophilia 2016 World Congress

CSL Behring today announced that the company has named five recipients of the 2016 CSL Behring Professor Heimburger Award for coagulation research at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla. Now in its ninth year, the global awards program supports the work of emerging coagulation specialists seeking to advance their innovative research. This year, CSL Behring awarded a total of five start-up grants, worth approximately $110,000 total.

Recipients of the 2016 CSL Behring Professor Heimburger Award were selected from more than 55 applicants, from 14 countries, by an independent committee of world-renowned clinicians, based on the potential of their research proposals. This year’s winners, whose institution will receive approximately $22,000 each, include:

  • Antonino Cannavò, M.D.
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Italy)
    Proposal: The role of non-neutralizing antibodies directed against factor VIII in hemophilia A patients enrolled in the SIPPET study
  • Christopher Ng, M.D.
    University of Colorado Denver, University of Colorado Hemophilia and Thrombosis Center (U.S.)
    Proposal: Multi-system evaluation of von Willebrand factor, function in Type 1 von Willebrand disease mutations
  • Alessandro Casini, M.D.
    University Hospitals of Geneva, Unit of Angiology and Haemostasis (Switzerland)
    Proposal: Fibrin clot structure to assess phenotype in patients with congenital dysfibrinogenemia
  • Johan Boender, M.D.
    Erasmus University Medical Center Rotterdam (Netherlands)
    Proposal: WUB-Kids: a prospective study of children with moderate and severe von Willebrand disease
  • Michiel Coppens, M.D.
    Academisch Medisch Centrum (Netherlands)
    Proposal: Biomarkers to detect subclinical arthropathy and predict long-term clinical arthropathy in patients with hemophilia

"For a century, CSL Behring has been driven by its promise to develop and deliver innovative treatments that save lives and/or improve the quality of life for people with serious medical conditions," said Jens Oltrogge, Ph.D., Head of Commercial Development Coagulation, CSL Behring. "As a global biotherapeutics leader, it’s critical to support emerging coagulation researchers who, like Professor Heimburger, are pioneers in improving the care for patients with bleeding disorders. We would like to congratulate all of the recipients of the 2016 CSL Behring Professor Heimburger Award and wish them success with their research."

More information about the CSL Behring Professor Heimburger Awards, including the names of previous winners, can be found at:

About Professor Heimburger

Professor Norbert Heimburger was an employee of CSL Behring for more than 30 years and devoted his work to blood coagulation. One of his major contributions in this area was the development of virus-safe plasma products based on pasteurization, a development that led CSL Behring to produce the world’s first virus-inactivated factor VIII concentrate to treat hemophilia patients.

About CSL Behring

CSL Behring is a global biotherapeutics leader which is driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs more than 16,000 people with operations in more than 30 countries. For more information about CSL Behring visit or follow us at



Greg Healy
CSL Behring
Office: 610-878-4841
Mobile: 610-906-4564

Get our latest news releases in your inbox
* Required Fields